Richard Kefford

Richard Kefford

UNVERIFIED PROFILE

Are you Richard Kefford?   Register this Author

Register author
Richard Kefford

Richard Kefford

Publications by authors named "Richard Kefford"

Are you Richard Kefford?   Register this Author

100Publications

22832Reads

12Profile Views

in a patient on dose-dense chemotherapy for early breast cancer.

Respirol Case Rep 2019 Oct 5;7(7):e00459. Epub 2019 Jul 5.

Cancer Program, MQ Health Macquarie University Hospital Sydney New South Wales Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/rcr2.459DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611505PMC
October 2019

Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors.

Pigment Cell Melanoma Res 2019 Sep 13. Epub 2019 Sep 13.

Department of Biomedical Science, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12824DOI Listing
September 2019

Reply to E. Hindié and K.R. Hess.

J Clin Oncol 2019 May 2;37(15):1356-1358. Epub 2019 Apr 2.

Georgina V. Long, MD, PhD, Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, NSW, Australia; Reinhard Dummer, MD, University Hospital Zürich Skin Cancer Center, Zürich, Switzerland; Dirk Schadendorf, MD, PhD, University Hospital Essen, Essen, Germany, and German Cancer Consortium, Heidelberg, Germany; Mario Santinami, MD, Fondazione Istituto Nazionale Tumori, Milan, Italy; Victoria Atkinson, MD, Princess Alexandra Hospital, Gallipoli Medical Research Foundation, and University of Queensland, Brisbane, QLD, Australia; Mario Mandalà, MD, Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy; Vanna Chiarion-Sileni, MD, Veneto Institute of Oncology-Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy; James Larkin, MD, PhD, Royal Marsden National Health Service Foundation Trust, London, United Kingdom; Marta Nyakas, MD, Oslo University Hospital, Oslo, Norway; Caroline Dutriaux, MD, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux, France; Andrew Haydon, MD, PhD, The Alfred Hospital, Melbourne, VIC, Australia; Caroline Robert, MD, PhD, Institute Gustave Roussy, Paris, France; Laurent Mortier, MD, PhD, Université de Lille, Institut National de la Santé et de la Recherche Médicale U 1189, Centre Hospitalier Universitaire Lille, Lille, France; Jacob Schachter, MD, PhD, Sheba Medical Center, Tel HaShomer, Israel, and Tel Aviv University, Tel Aviv, Israel; Thierry Lesimple, MD, MSc, Centre Eugène Marquis, Rennes, France; Ruth Plummer, MD, PhD, Freeman Hospital and Newcastle University, Newcastle upon Tyne, United Kingdom; Kohinoor Dasgupta, PhD, Novartis Healthcare, Hyderabad, India; Tomas Haas, PhD, Novartis AG, Basel, Switzerland; Mark Shilkrut, MD, PhD and Eduard Gasal, MD, Novartis Pharmaceuticals, East Hanover, NJ; Richard Kefford, MD, PhD, Melanoma Institute Australia, The University of Sydney, Macquarie University, and Westmead Hospital, Sydney, NSW, Australia; John M. Kirkwood, MD, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA; and Axel Hauschild, MD, University Hospital Schleswig-Holstein, Kiel, Germany.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.19.00004
Publisher Site
http://dx.doi.org/10.1200/JCO.19.00004DOI Listing
May 2019

Evaluation of commercial kits for purification of circulating free DNA.

Cancer Genet 2018 12 29;228-229:21-27. Epub 2018 Aug 29.

Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW 2109, Australia; The Poche Centre, Melanoma Institute Australia, NSW 2065, Australia. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S22107762183025
Publisher Site
http://dx.doi.org/10.1016/j.cancergen.2018.08.005DOI Listing
December 2018

Oncogenic signaling in uveal melanoma.

Pigment Cell Melanoma Res 2018 11 23;31(6):661-672. Epub 2018 May 23.

Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12708DOI Listing
November 2018

Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma.

J Clin Oncol 2018 Oct 22:JCO1801219. Epub 2018 Oct 22.

Axel Hauschild, University Hospital Schleswig-Holstein, Kiel; Dirk Schadendorf, University Hospital Essen, Essen; German Cancer Consortium, Heidelberg, Germany; Reinhard Dummer, University Hospital Zürich Skin Cancer Center, Zürich; Tomas Haas, Novartis AG, Basel, Switzerland; Mario Santinami, Fondazione Istituto Nazionale Tumori, Milan; Mario Mandalà, Papa Giovanni XXIII Cancer Center Hospital, Bergamo; Vanna Chiarion-Sileni, Veneto Institute of Oncology-Istituto di Ricovero e Cura a Carattere Scientifico, Padova, Italy; Victoria Atkinson, Princess Alexandra Hospital; Gallipoli Medical Research Foundation; University of Queensland, Brisbane, Queensland; Andrew Haydon, The Alfred Hospital, Melbourne, Victoria; Richard Kefford, Macquarie University; Westmead Hospital; Richard Kefford and Georgina V. Long, Melanoma Institute Australia; University of Sydney; Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia; James Larkin, Royal Marsden National Health Service Foundation Trust, London; Ruth Plummer, Freeman Hospital and Newcastle University, Newcastle upon Tyne, United Kingdom; Marta Nyakas, Oslo University Hospital, Oslo, Norway; Caroline Dutriaux, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux; Caroline Robert, Institute Gustave Roussy, Paris; Laurent Mortier, Université de Lille, Institut National de la Santé et de la Recherche Médicale U1189, Centre Hospitalier Universitaire de sa Region Lille, Lille; Thierry Lesimple, Centre Eugène Marquis, Rennes, France; Jacob Schachter, Sheba Medical Center, Tel Hashomer; Tel Aviv University, Tel Aviv, Israel; Kohinoor Dasgupta, Novartis Healthcare, Hyderabad, India; Mark Shilkrut and Eduard Gasal, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and John M. Kirkwood, UPMC Hillman Cancer Center; University of Pittsburgh, Pittsburgh, PA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.01219
Publisher Site
http://dx.doi.org/10.1200/JCO.18.01219DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286159PMC
October 2018

Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma.

Oncogenesis 2018 Sep 20;7(9):72. Epub 2018 Sep 20.

Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41389-018-0081-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6148266PMC
September 2018

Neoadjuvant systemic therapy for breast cancer: the Westmead experience.

ANZ J Surg 2018 Jun 18;88(6):640-644. Epub 2017 Sep 18.

Department of Surgery, Westmead Hospital, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ans.14158DOI Listing
June 2018

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.

J Clin Oncol 2018 06 28;36(17):1668-1674. Epub 2017 Dec 28.

Caroline Robert, Gustave Roussy Cancer Campus and Paris Sud University, Villejuif Paris-Sud, France; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Adil Daud, University of California, San Francisco, San Francisco, CA; Jedd D. Wolchok, Ludwig Center, Memorial Sloan Kettering Cancer Center, New York, NY; Anthony M. Joshua, The Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H Lee Moffitt Cancer Center, Tampa; Richard W. Joseph, Mayo Clinic Cancer Center-Florida, Jacksonville, FL; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, UPMC Hillman Cancer Center, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead; Melanoma Institute Australia, Wollstonecraft; and Macquarie University, MQ Health, Health Sciences Centre; Peter Hersey, University of Sydney, Sydney, New South Wales, Australia; Jin Zhang, James Anderson, Scott J. Diede, and Scot Ebbinghaus, Merck & Co., Inc., Kenilworth, NJ; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.75.6270
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.75.6270DOI Listing
June 2018

Interferon Signaling Is Frequently Downregulated in Melanoma.

Front Immunol 2018 21;9:1414. Epub 2018 Jun 21.

Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2018.01414DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021492PMC
June 2018

Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma.

Pigment Cell Melanoma Res 2018 05 7;31(3):404-410. Epub 2017 Dec 7.

Melanoma Institute Australia, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12675DOI Listing
May 2018

Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.

J Clin Oncol 2018 03 9;36(7):667-673. Epub 2017 Oct 9.

Georgina V. Long, University of Sydney, and Royal North Shore Hospital; Richard Kefford, Macquarie University, Sydney, and Westmead Hospital, Westmead, New South Wales; Jonathan Cebon, Ludwig Institute for Cancer Research, Melbourne, Victoria, Australia; Zeynep Eroglu, Moffitt Cancer Center, Tampa, FL; Jeffrey Infante, Tennessee Oncology; Douglas B. Johnson, Vanderbilt-Ingram Cancer Center, Nashville, TN; Sapna Patel, The University of Texas MD Anderson Cancer Center, Houston, TX; Adil Daud, University of California, San Francisco, San Francisco; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA; Rene Gonzalez, University of Colorado, Denver, CO; Lynn Schuchter, University of Pennsylvania, Philadelphia, PA; William Sharfman, Sidney Kimmel Cancer Center, Baltimore, MD; Robert McWilliams, Mayo Clinic, Rochester, MN; Mario Sznol, Yale University, New Haven, CT; Suman Redhu, Eduard Gasal, and Bijoyesh Mookerjee, Novartis, East Hanover, NJ; Jeffrey Weber, New York University Langone Medical Center, New York, NY; and Keith T. Flaherty, Dana-Farber/Harvard Cancer Center, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.74.1025
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.74.1025DOI Listing
March 2018

Liquid biomarkers in melanoma: detection and discovery.

Mol Cancer 2018 01 17;17(1). Epub 2018 Jan 17.

Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12943-018-0757-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5772714PMC
January 2018

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.

N Engl J Med 2017 11 10;377(19):1813-1823. Epub 2017 Sep 10.

From the Melanoma Institute Australia, University of Sydney, Royal North Shore and Mater Hospitals (G.V.L.), and Macquarie University, Melanoma Institute Australia, University of Sydney, and Westmead Hospital (R.K.), Sydney, Princess Alexandra Hospital, Gallipoli Medical Research Foundation, University of Queensland, Brisbane (V.A.), and Alfred Hospital, Melbourne, VIC (A. Haydon) - all in Australia; University Hospital Schleswig-Holstein, Kiel (A. Hauschild), and University Hospital Essen, Essen, and the German Cancer Consortium, Heidelberg (D.S.) - all in Germany; Fondazione Istituto Nazionale Tumori, Milan (M.S.), Papa Giovanni XXIII Cancer Center Hospital, Bergamo (M.M.), and the Melanoma Oncology Unit, Veneto Oncology Institute, Padua (V.C.-S.) - all in Italy; Rikshospitalet-Radiumhospitalet, Oslo (M.N.); Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux (C.D.), Institute Gustave Roussy, Paris (C.R.), Université de Lille, INSERM Unité 1189, Centre Hospitalier Régional Universitaire de Lille, Lille (L.M.), and the Medical Oncology Department, Centre Eugène Marquis, Rennes (T.L.) - all in France; Ella Institute for Melanoma, Sheba Medical Center, Tel Hashomer, Israel (J.S.); Royal Marsden NHS Foundation Trust, London (J. Larkin), and Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne (R.P.) - both in the United Kingdom; Novartis Pharmaceuticals, East Hanover, NJ (R.J., P.Z., B.M., J. Legos); University Hospital Zürich Skin Cancer Center, Zurich, Switzerland (R.D.); and the Melanoma Program, Hillman UPMC Cancer Center, University of Pittsburgh, Pittsburgh (J.M.K.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1708539
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1708539DOI Listing
November 2017

Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697).

J Clin Oncol 2017 Mar 30;35(8):885-892. Epub 2017 Jan 30.

Sanjiv S. Agarwala, Saint Luke's University Hospital, Easton; Uma N. Rao, Ahmad A. Tarhini, Terry L. Evans, and John M. Kirkwood, University of Pittsburgh Medical Center, Pittsburgh, PA; Sandra J. Lee, and Waiki Yip, Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA; Gary I. Cohen, Greater Baltimore Medical Center, Baltimore, MD; Douglas S. Reintgen, Lakeland Regional Cancer Center, Lakeland; Vernon K. Sondak, H. Lee Moffitt Cancer Center, Tampa, FL; Joanna M. Brell, MetroHealth Medical Center, Cleveland; William E. Carson, The Ohio State University Comprehensive Cancer Center, Columbus, OH; Mark R. Albertini, University of Wisconsin Hospital, Madison, WI; Michael B. Atkins, Georgetown Medical Center, Washington, DC; Shaker R. Dakhil, Cancer Center of Kansas, Wichita, KS; Robert M. Conry, University of Alabama at Birmingham, Birmingham, AL; Jeffrey A. Sosman, Vanderbilt University, Nashville; Alberto S. Pappo, Saint Jude Children's Research Hospital Oncology, Memphis, TN; Lawrence E. Flaherty, Wayne State University/Karmanos Cancer Institute, Detroit, MI; Michael G. Smylie, Cross Cancer Institute, Edmonton, Canada; and Richard F. Kefford, Sydney West Area Health Service, Westmead, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.2951DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455684PMC
March 2017

Pharmacokinetics of dabrafenib in a patient with metastatic melanoma undergoing haemodialysis.

Pigment Cell Melanoma Res 2017 01;30(1):68-71

Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12557DOI Listing
January 2017

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.

J Clin Oncol 2016 12 31;34(34):4102-4109. Epub 2016 Oct 31.

Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.67.2477
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.67.2477DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562434PMC
December 2016

Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series.

Br J Cancer 2016 Nov 6;115(11):1280-1284. Epub 2016 Oct 6.

Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione 'G. Pascale', Via Mariano Semmola, 80131 Napoli, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2016.321DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129828PMC
November 2016

Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring-The TADE Study.

Clin Cancer Res 2016 07 4;22(13):3164-71. Epub 2016 Feb 4.

Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, Australia. Sydney Medical School - Westmead, University of Sydney, Sydney, Australia. Faculty of Medicine and Health Sciences, Macquarie University, Sydney Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-1470DOI Listing
July 2016

PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges.

Immunotherapy 2016 06;8(6):733-46

Crown Princess Mary Cancer Centre, Westmead hospital, Westmead, NSW 2145, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2016-0022DOI Listing
June 2016

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.

J Clin Oncol 2016 05 7;34(13):1510-7. Epub 2016 Mar 7.

F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Richard Kefford, Westmead Hospital, Melanoma Institute Australia, and Macquarie University; Peter Hersey, University of Sydney, Sydney, Australia; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; Adil Daud, University of California San Francisco, San Francisco; Omid Hamid, The Angeles Clinic and Research Institute; Antoni Ribas, University of California Los Angeles, Los Angeles, CA; Caroline Robert, Gustave-Roussy and Paris-Sud University, Villejuif-Paris-Sud, France; Tara C. Gangadhar, Abramson Cancer Center, Philadelphia, PA; Anthony M. Joshua, Princess Margaret Hospital, Toronto, Ontario, Canada; Roxana Dronca, Mayo Clinic, Rochester, MN; Darcy Hille, Dahai Xue, Xiaoyun Nicole Li, S. Peter Kang, Scot Ebbinghaus, and Andrea Perrone, Merck, Kenilworth, NJ; and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.0391DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070547PMC
May 2016

Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma.

Melanoma Res 2016 Apr;26(2):202-4

aCrown Princess Mary Cancer Centre bBlood and Marrow Transplant Service, Department of Haematology cDepartment of Clinical Immunology and Allergy, Westmead Hospital dFaculty of Medicine, The University of Sydney eMelanoma Institute Australia fFaculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000232DOI Listing
April 2016

Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.

J Am Acad Dermatol 2016 Mar 12;74(3):455-61.e1. Epub 2016 Jan 12.

Department of Dermatology, Westmead Hospital, Sydney, Australia; Sydney Medical School, University of Sydney, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2015.10.029DOI Listing
March 2016

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

J Clin Oncol 2016 Mar 25;34(8):871-8. Epub 2016 Jan 25.

Georgina V. Long, Melanoma Institute Australia; The University of Sydney; Richard F. Kefford, Melanoma Institute Australia; The University of Sydney; Macquarie University, Sydney; Westmead Hospital, Westmead; Jonathan Cebon, Austin Health, Melbourne, Victoria, Australia; Jeffrey S. Weber and Ragini Kudchadkar, Moffitt Cancer Center, Tampa, FL; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute/Tennessee Oncology; Kevin B. Kim, California Pacific Medical Center; Adil Daud, Alain Algazi, University of California, San Francisco, San Francisco; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA; Rene Gonzalez, Karl Lewis, University of Colorado; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Jeffrey A. Sosman, Igor Puzanov, Vanderbilt University Medical Center, Nashville, TN; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Elizabeth Cunningham, Merck; Peng Sun, Amy S. Kline, Heather Del Buono, Diane Opatt McDowell, GlaxoSmithKline, Philadelphia, PA; Donald Lawrence and Kiran Patel, Incyte Corporation, Wilmington, DE; and Keith T. Flaherty, Massachusetts General Hospital Cancer Center, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.62.9345
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.62.9345DOI Listing
March 2016

The molecular profile of metastatic melanoma in Australia.

Pathology 2016 Feb 18;48(2):188-93. Epub 2016 Jan 18.

Melanoma Institute Australia, Sydney, NSW, Australia; The University of Sydney, Sydney, NSW, Australia; Royal North Shore Hospital, Sydney, NSW, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pathol.2015.12.008DOI Listing
February 2016

Acute Radiation Skin Toxicity Associated With BRAF Inhibitors.

J Clin Oncol 2016 Jan 27;34(3):e17-20. Epub 2014 May 27.

Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead; The University of Sydney, Sydney, New South Wales, Australia

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.49.0565DOI Listing
January 2016

Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma.

Crit Rev Oncol Hematol 2015 Dec 28;96(3):385-98. Epub 2015 Aug 28.

Centre for Cancer Research, Westmead Millennium Institute, Westmead, New South Wales, Australia; Melanoma Institute Australia, Sydney, New South Wales, Australia; Faculty of Medicine and Health Science, Macquarie University, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2015.08.021DOI Listing
December 2015

Treatment algorithms in stage IV melanoma.

Am J Ther 2015 Jan-Feb;22(1):61-7

1Service of Oncology, Hospital La Paz, Madrid, Spain; 2Department of Dermatology, Hopital Ste Marguerite, Marseille, France; 3Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland; 4Department of Sarcoma and Melanoma, M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; 5Department of Dermatology (CR), and General Director (AE), Institute Gustave Roussy, Villejuif Cedex, France; 6First Department of Medicine, University of Athens Medical School, Athens, Greece; 7Department of Oncology, Westmead Hospital and Melanoma Institute Australia, University of Sydney, Sydney, Australia; 8Service of Oncology, Clinica Universitaria de Navarra, Pamplona, Spain; 9Department of Dermatology, University of Kiel, Kiel, Germany; and 10Department of Dermatology, University Hospital Essen, Essen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MJT.0b013e31829e885cDOI Listing
September 2015

Immune checkpoint inhibitors in melanoma.

Melanoma Manag 2015 Aug 10;2(3):267-284. Epub 2015 Aug 10.

Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/mmt.15.17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094677PMC
August 2015

PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.

Clin Cancer Res 2015 Jul 21;21(14):3140-8. Epub 2015 Jan 21.

Melanoma Institute Australia, North Sydney, New South Wales, Australia. Sydney Medical School, the University of Sydney, Sydney, New South Wales, Australia. Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2023DOI Listing
July 2015

Diffuse melanosis cutis in the setting of BRAF(V600E) mutant melanoma and treatment with targeted therapies.

Australas J Dermatol 2015 May 27;56(2):128-30. Epub 2014 Aug 27.

Department of Dermatology, Westmead Hospital, Westmead, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajd.12187DOI Listing
May 2015

PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials.

Pigment Cell Melanoma Res 2015 May 22;28(3):245-53. Epub 2014 Dec 22.

Melanoma Institute Australia, Sydney, NSW, Australia; Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/pcmr.12340
Publisher Site
http://dx.doi.org/10.1111/pcmr.12340DOI Listing
May 2015

Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy.

J Am Acad Dermatol 2015 May 3;72(5):809-15.e1. Epub 2015 Mar 3.

Department of Dermatology, Westmead Hospital, Westmead, Australia; Sydney Medical School, University of Sydney, Sydney, Australia. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01909622150005
Publisher Site
http://dx.doi.org/10.1016/j.jaad.2015.01.018DOI Listing
May 2015

New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma.

J Clin Oncol 2015 Apr 12;33(11):e52-6. Epub 2014 May 12.

Melanoma Institute Australia; The University of Sydney and Westmead Institute for Cancer Research, Sydney, Australia

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.51.5783DOI Listing
April 2015

Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom.

Hered Cancer Clin Pract 2014 20;12(1):20. Epub 2014 Nov 20.

Dermatology Department and Biochemistry and Molecular Genetics Department, Melanoma Unit, Hospital Clinic, Instituto de Investigaciones Biomédicas August Pi I Sunyer (IDIBAPS), Barcelona, Spain ; Centro Investigación Biomédica en Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1897-4287-12-20DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4361137PMC
March 2015

Targeted BRAF inhibition impacts survival in melanoma patients with high levels of Wnt/β-catenin signaling.

PLoS One 2014 14;9(4):e94748. Epub 2014 Apr 14.

Melanoma Institute of Australia, Sydney, New South Wales, Australia; The University of Sydney, Sydney, New South Wales, Australia; Westmead Institute for Cancer Research, Westmead Millennium Institute, Westmead, New South Wales, Australia; Westmead Hospital, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0094748PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3986217PMC
January 2015

Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.

Clin Cancer Res 2015 Jan 4;21(1):98-105. Epub 2014 Nov 4.

Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead, New South Wales, Australia. Australian School of Advanced Medicine, Macquarie University, New South Wales, Australia. Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-0759DOI Listing
January 2015

Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma.

J Immunother 2015 Jan;38(1):37-9

*The Crown Princess Mary Cancer Centre ∥Rheumatology Department, Westmead Hospital †Melanoma Institute Australia ‡Sydney Medical School, The University of Sydney §Westmead Institute for Cancer Research, Westmead Millennium Institute, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
https://insights.ovid.com/crossref?an=00002371-201501000-000
Publisher Site
http://dx.doi.org/10.1097/CJI.0000000000000060DOI Listing
January 2015

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.

Nat Commun 2014 Dec 2;5:5694. Epub 2014 Dec 2.

1] Precision Cancer Therapy Laboratory, Australian School of Advanced Medicine, Macquarie University, Sydney, New South Wales 2109, Australia [2] Westmead Institute for Cancer Research, The University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales 2145, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncomms6694DOI Listing
December 2014

Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib.

Australas J Dermatol 2014 Nov 9;55(4):250-4. Epub 2013 Dec 9.

Department of Dermatology, Westmead Hospital, Sydney, New South Wales, Australia; Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajd.12124DOI Listing
November 2014

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.

J Clin Oncol 2014 Nov 6;32(33):3697-704. Epub 2014 Oct 6.

Douglas B. Johnson and Jeffrey A. Sosman, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Keith T. Flaherty and Donald P. Lawrence, Massachusetts General Hospital Cancer Center, Boston MA; Jeffrey S. Weber and Geoffrey T. Gibney, Moffitt Cancer Center, Tampa, FL; Kevin B. Kim and Gerald S. Falchook, University of Texas MD Anderson Cancer Center, Houston, TX; Richard F. Kefford and Georgina V. Long, Melanoma Institute Australia, University of Sydney and Westmead Hospital, Sydney, New South Wales; Jonathan Cebon, Joint Ludwig-Austin Oncology Unit, Austin Health, Melbourne, Victoria, Australia; Omid Hamid, Angeles Clinic and Research Institute, Los Angeles; Alain Algazi and Adil Daud, University of California, San Francisco, San Francisco, CA; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Peng Sun, Shonda Little, and Elizabeth Cunningham, GlaxoSmithKline, Philadelphia, PA; William H. Sharfman, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; Robert R. McWilliams, Mayo Clinic, Rochester, MN; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Karl Lewis and Rene Gonzalez, University of Colorado, Denver, CO; and Kiran Patel, Incyte, Wilmington, DE.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.3535DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226803PMC
November 2014

Acneiform eruption in a patient with metastatic melanoma after ceasing combination dabrafenib/trametinib therapy.

Melanoma Res 2014 Oct;24(5):501-3

Departments of aDermatology bMedical Oncology, Westmead Hospital cSydney Medical School, The University of Sydney dMelanoma Institute Australia, Sydney, New South Wales, Australia eDepartment of Dermatology, School of Medicine, Pontificia Universidad Catolica de Chile, Santiago, Chile.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000096DOI Listing
October 2014

The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition.

Cancer 2014 Oct 1;120(20):3142-53. Epub 2014 Jul 1.

Melanoma Institute Australia, Sydney, New South Wales, Australia; Department of Medical Oncology, Crown Princess Mary Cancer Center, Westmead Hospital, Sydney, New South Wales, Australia; University of Sydney, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.28851DOI Listing
October 2014

Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma.

Melanoma Res 2014 Oct;24(5):468-74

aWestmead Hospital bWestmead Institute for Cancer Research, Westmead cMelanoma Institute Australia dSydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000110DOI Listing
October 2014

Reply to M. Perier-Muzet et al.

J Clin Oncol 2014 Oct 2;32(28):3203. Epub 2014 Sep 2.

Melanoma Institute Australia; and Sydney Medical School, The University of Sydney, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.56.8477DOI Listing
October 2014

Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors.

Mod Pathol 2014 Sep 17;27(9):1193-202. Epub 2014 Jan 17.

1] Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/modpathol.2013.226DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107197PMC
September 2014

Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436).

Clin Cancer Res 2014 Sep 23;20(17):4449-58. Epub 2014 Jun 23.

Melanoma Institute Australia and University of Sydney, New South Wales, Australia. Westmead Institute for Cancer Research, Westmead Millennium Institute, and Department of Medical Oncology, Westmead Hospital, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-14-0887DOI Listing
September 2014

Identification of a melanoma susceptibility locus and somatic mutation in TET2.

Carcinogenesis 2014 Sep 30;35(9):2097-101. Epub 2014 Jun 30.

Department of Epidemiology and Biostatistics, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center of Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China, Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA, Channing Division of Network Medicine and Department of Dermatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA, Department of Epidemiology, Fairbanks School of Public Health, Indiana University, Indianapolis, IN 46202, USA, Simon Cancer Center, Indiana University, Indianapolis, IN 46202, USA and Department of Dermatology, School of Medicine, Indiana University, Indianapolis, IN 46202, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/carcin/bgu140DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4146422PMC
September 2014

Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.

Mol Oncol 2014 May 15;8(3):544-54. Epub 2014 Jan 15.

Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales 2145, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2014.01.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5528644PMC
May 2014

BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.

Clin Cancer Res 2014 Apr 24;20(7):1965-77. Epub 2014 Jan 24.

Authors' Affiliations: Westmead Institute for Cancer Research, The University of Sydney at Westmead Millennium Institute; Departments of Medical Oncology and Surgical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead; Melanoma Institute Australia; Disciplines of Pathology, Medicine, and Surgery, Sydney Medical School, The University of Sydney, Sydney; Departments of Melanoma and Surgical Oncology and Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-3122DOI Listing
April 2014

Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas.

Pathology 2014 Apr;46(3):193-8

1The University of Sydney, Sydney 2Melanoma Institute Australia, North Sydney 3Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia 4Canterbury Health Laboratories, Christchurch, New Zealand 5Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst 6Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAT.0000000000000077DOI Listing
April 2014

Incidence of new primary melanomas after diagnosis of stage III and IV melanoma.

J Clin Oncol 2014 Mar 2;32(8):816-23. Epub 2013 Dec 2.

Lisa Zimmer and Dirk Schadendorf, University Hospital, University Duisburg-Essen, Essen, Germany; Lauren E. Haydu, Alexander M. Menzies, Richard A. Scolyer, Richard F. Kefford, John F. Thompson, and Georgina V. Long, Melanoma Institute Australia; Alexander M. Menzies, Richard A. Scolyer, Richard F. Kefford, and Georgina V. Long, Sydney Medical School, The University of Sydney; Richard A. Scolyer and John F. Thompson, Royal Prince Alfred Hospital; Lauren E. Haydu and John F. Thompson, The University of Sydney; John F. Thompson, Mater Hospital, Sydney; Richard F. Kefford and Georgina V. Long, Westmead Institute for Cancer Research, Westmead Hospital, Westmead, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.49.5572DOI Listing
March 2014

Intrapatient homogeneity of BRAFV600E expression in melanoma.

Am J Surg Pathol 2014 Mar;38(3):377-82

*Melanoma Institute Australia Discipline of †Medicine §Pathology #Surgery, The University of Sydney Departments of **Melanoma and Surgical Oncology ‡Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital ∥Department of Medicine, Westmead Hospital ¶Westmead Institute for Cancer Research, Westmead Hospital ††The Kinghorn Cancer Centre, Garvan Institute of Medical Research ‡‡St Vincent's Clinical School, University of New South Wales, Sydney, Australia.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/ajsp/2014/03000/Intrapatient_Ho
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/PAS.0000000000000136DOI Listing
March 2014

Patterns of response and progression in patients with BRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib.

Cancer 2014 Feb 5;120(4):530-6. Epub 2013 Nov 5.

Westmead Hospital, Westmead, Australia; Melanoma Institute Australia, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.28445DOI Listing
February 2014

A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.

Cancer Discov 2014 Jan 21;4(1):69-79. Epub 2013 Nov 21.

1The Division of Dermatology, Department of Medicine, 2Division of Surgical Oncology, Department of Surgery, 3Division of Hematology and Oncology, Department of Medicine, 4Jonsson Comprehensive Cancer Center, 5Department of Molecular and Medical Pharmacology, 6David Geffen School of Medicine, University of California, Los Angeles, California; 7Melanoma Institute of Australia, 8Royal Prince Alfred Hospital, 9Westmead Millennium Institute, and 10Westmead Hospital, University of Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0279DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893054PMC
January 2014

Paradoxical oncogenesis: are all BRAF inhibitors equal?

Pigment Cell Melanoma Res 2013 Sep 19;26(5):611-5. Epub 2013 Jul 19.

Melanoma Institute Australia, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12132DOI Listing
September 2013

Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.

J Clin Oncol 2013 Sep 5;31(26):3205-11. Epub 2013 Aug 5.

Paolo A. Ascierto, Ester Simeone, Instituto Nazionale Tumori Fondazione "G. Pascale," Napoli, Italy; David Minor, California Pacific Center for Melanoma Research and Treatment, San Francisco; Antoni Ribas, Jonsson Comprehensive Cancer Center, University of California, Los Angeles; Omid Hamid, Experimental Therapeutics/Immunotherapy, The Angeles Clinic and Research Institute, Los Angeles, CA; Anne O'Hagan, Niki Arya, Mary Guckert, Anne-Marie Martin, Jolly Mazumdar, Vicki L. Goodman, GlaxoSmithKline Oncology, Collegeville; Ravi Amaravadi, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Kevin B. Kim, The University of Texas MD Anderson Cancer Center, Houston, TX; Celeste Lebbe, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Paris, Université Paris Diderot, Paris; Jean-Jacques Grob, Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille, Hôpital Timone, Marseille, France; Dirk Schadendorf, University Hospital Essen, Essen; Tabea Wilhelm, Uwe Trefzer, Charité-Universitätsmedizin, Berlin, Germany; Richard F. Kefford, Georgina V. Long, Westmead Hospital and Melanoma Institute Australia, University of Sydney, Sydney, Australia.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2013.49.8691
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.49.8691DOI Listing
September 2013

Reply to K.S. Wilson et al.

J Clin Oncol 2013 Aug;31(22):2836-7

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.50.2120DOI Listing
August 2013

Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.

Pigment Cell Melanoma Res 2013 Jul 13;26(4):518-26. Epub 2013 May 13.

Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, NSW, Australia.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/pcmr.12107
Publisher Site
http://dx.doi.org/10.1111/pcmr.12107DOI Listing
July 2013

Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma.

Mol Cancer Ther 2013 Jul 3;12(7):1332-42. Epub 2013 May 3.

Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, NSW 2145, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-13-0011DOI Listing
July 2013